Healthcare Industry News: Exubera
News Release - September 13, 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Sept. 13, 2006--FibroGen, Inc. today announced the appointment of Melissa L. Grigorieff as Vice President of Marketing. Ms. Grigorieff brings to FibroGen 16 years of experience in pharmaceutical marketing and healthcare communications. At FibroGen, Ms. Grigorieff will provide market insights to guide the development of FibroGen's products. She will also oversee development of an internal commercial organization to enable the success of the company's product portfolio.Ms. Grigorieff was most recently Senior Director, Worldwide Marketing of Diabetes and Obesity products at Pfizer, Inc. In this role, Ms. Grigorieff led commercial strategy for Pfizer's clinical development and licensing programs in diabetes and obesity. Chiefly, she was responsible for leading the commercial aspects of the development and global launch of Exubera® (inhaled human insulin).
Prior to joining Pfizer, Ms. Grigorieff worked at Novartis Pharmaceuticals, most recently as US Product Director for the antihypertensive, Lotrel®. Prior to joining Novartis, Ms. Grigorieff spent seven years in healthcare public relations where she developed and managed product launch communications, issues management and disease awareness programs for biotechnology and pharmaceutical clients.
"Melissa joins FibroGen at a critical time as we bring multiple compounds into later phases of clinical development," said Thomas B. Neff, Chief Executive Officer of FibroGen. "I look forward to Melissa's contributions as we develop a leading product portfolio supported by a strong, vertically-integrated biopharmaceutical organization."
Ms. Grigorieff received an MBA from the Harvard Graduate School of Business Administration and a BA from Yale College.
About FibroGen
FibroGen, Inc., is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen's proprietary cosmetic dermal filler and biomaterials supply business.
For more information about FibroGen, Inc., please visit www.fibrogen.com.
Source: FibroGen
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
